Ask AI
ProCE Banner Activity

BREATHER Plus: Short-Cycle vs Continuous ART in Adolescents Living With HIV Receiving DTG + TDF/3TC in Sub-Saharan Africa

Slideset

In the BREATHER Plus trial, the rate of confirmed viral rebound was inferior among adolescents living with HIV taking DTG + TDF/3TC as short-cycle therapy vs continuous therapy ART despite similar safety and adherence.

Released: July 17, 2025

Expiration: January 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC  in partnership with the International AIDS Society

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner